Diseases [C] » Neoplasms [C04] » Neoplastic Processes » Neoplasm Metastasis
Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes » Neoplastic Processes » Neoplasm Metastasis
Description
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. MeSH
Hierarchy View
Subtype Terms (6)
Extranodal Extension
1 approved drug
Lymphatic Metastasis
5 drugs (4 approved, 1 experimental)
Neoplasm Seeding
1 experimental drug
Neoplasms, Unknown Primary
15 drugs (13 approved, 2 experimental)
Neoplastic Cells, Circulating
25 drugs (23 approved, 2 experimental)
Phase 4 Indicated Drugs (39)
Phase 3 Indicated Drugs (132)
Phase 2 Indicated Drugs (217)
2-(5-fluoro-pentyl)-2-methyl-malonic-acid
antigen pulsed dendritic cells
mart-1, gp100, tyrosinase peptides
mart-1 peptide pulsed dendritic cells
peripheral blood progenitor cells carrying mdr1
radiolabeled albumin technetium Tc-99m albumin colloid kit (Microlite)
Phase 1 Indicated Drugs (256)
1-(2-[18f]fluoroethyl)-l-tryptophan
adenoviral-mediated interferon-beta
allogeneic natural killer cells
anti-macrophage migration inhibitory factor antibody
autologous cd19/cd22 chimeric antigen receptor t-cells
autologous tumor infiltrating lymphocytes
autologous umbilical cord blood
ny-eso-1(157-165) peptide-pulsed autologous dendritic cell vaccine
ny-eso-1 reactive tcr retroviral vector transduced autologous pbl
oncolytic measles virus encoding thyroidal sodium iodide symporter
personalized neoantigen vaccine
proteasome sirna and tumor antigen rna-transfected dendritic cells
Organization Involved with Phase 4 Indications (92)
All India Institute of Medical Sciences
Badalona Hospital Germans Trias i Pujol
Chinese Society of Lung Cancer
Clinica Universidad de Navarra
Complejo Hospitalario La Mancha Centro
Dermatologic Cooperative Oncology Group
Effice Servicios Para la Investigacion S.L.
Hospital Universitari de Bellvitge
Huazhong University of Science and Technology
Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
People's Liberation Army of China
Qidong Gaitianli Medicines Co., Ltd
Shandong first medical University
Shandong Province Qianfoshan Hospital
Skane County Council Research & Development Foundation
Organization Involved with Phase 3 Indications (229)
Albert Einstein Israelite Hospital
Alpha Biopharma (Jiangsu) Co., Ltd.
Ambulancia Klinickej onkologie FNsP Nove Zamky
Anhui College of Traditional Chinese Medicine
Arbeitsgruppe Lebermetastasen und Tumoren
Assistance Publique - Hôpitaux de Paris
Australasian Gastro-Intestinal Trials Group
Beijing Municipal Administration of Hospitals
Betta Pharmaceuticals Co.,Ltd.
BioNumerik Pharmaceuticals, Inc.
Blokhin's Russian Cancer Research Center
British Columbia Cancer Agency
Canadian Institutes of Health Research (CIHR)
Cantonal Hospital of St. Gallen
Centre Hospitalier Intercommunal Creteil
Centre Hospital Universitaire Hop Huriez
Chengdu Kanghong Biotech Co.,Ltd.
Chinese Academy of Medical Sciences
Complexo Hospitalario Universitario de A Coruña
Departmental Hosptital of Vendee
Epidemiological and Clinical Research Information Network
European Organisation for Research and Treatment of Cancer
Federation Francophone de Cancerologie Digestive
Fondation Francaise de Cancerologie Digestive
Fundacion Favaloro Para La Docencia e Investigacion Medica
Gottfried Wilhelm Leibniz Universität Hannover
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Groupe Francais De Pneumo-Cancerologie
Guangdong Association of Clinical Trials
Hoosier Cancer Research Network
Hospicjum im. Ks. Eugeniusza Dutkiewicza SAC w Gdansku
Hospital de Cancer de Barretos - Fundacao Pio XII
Hospital Universitario Fundación Alcorcón
Institut de Cancerologie de l'Ouest Paul Papin
Instituto de Oncologia de Rosario
Instituto do Cancer do Estado de São Paulo
Italian Network for Tumor Biotherapy
King Khaled Eye Specialist Hospital
Masarykuv onkologicky ustav, Klinika komplexni onkologicke pece
Moorgreen Hospital, Southampton
National Cancer Institute, France
National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health (NIH)
National Shikoku Cancer Center
Niepliczny Zakad Opieki Zdrowotnej Zespo Medyczno-Opieku-Czy Alicja Kluczna
Nishinomiya Municipal Central Hospital
Northeastern Ohio Radiology Research and Education Fund
Oncocenter Onclogie Clinica S.R.L
Oncology department of Nemocnice Benesov
Pan American Collaborative Retina Study Group
Philipps University of Marburg
Poradnia Medycyny Paliatywnej Hospicjum Palium
Powiatowy Zespo Zakadow Opieki Zdrowotnej w Bdzinie, Oddzia Opieki Paliatywnej Szpital Czelad
Radiation Therapy Oncology Group
Royal Marsden Hospital NHS Trust
Russian Foundation of Technological Development
Sanwa Kagaku Kenkyusho Co., Ltd.
Sunshine Coast University, Australia
Swiss Group for Clinical Cancer Research
The Canadian Blood and Marrow Transplant Group
The Central Hospital of Lishui City
The First People's Hospital of Changzhou
The Serbsky State Scientific Center for Social and Forensic Psychiatry
University of Texas at Houston
University of Texas, San Antonio
Wilhelminenspital der Stadt Wien
ZAO NeuroVita Clinic of Interventional and Restorative Neurology and Therapy
ZonMw: The Netherlands Organisation for Health Research and Development
Organization Involved with Phase 2 Indications (352)
Alberta Innovates Health Solutions
American Society of Clinical Oncology
Association of Urogenital Oncology (AUO)
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie (ARTIC)
Association pour la Recherche sur le Temps Biologique et la Chronothérapie
Australia and New Zealand Melanoma Trials Group
Azienda Ospedaliera San Gerardo di Monza
Beijing InnoCare Pharma Tech Co., Ltd.
Beijing Tricision Biotherapeutics Inc
Biocompatibles International plc
BioMimetix Pharmaceutical, Inc.
Breast Cancer Research Foundation
California Pacific Medical Center Research Institute
Cancer Council New South Wales
Carolina Research Professionals, LLC
Case Western Reserve University
Catharina Hospital, Eindhoven, The Netherlands
Catholic University of Sacred Heart, Rome
Central European Society for Anticancer Drug Research (CESAR)
Centre Georges Francois Leclerc
Centre Hospitalier de la Région d'Annecy
City of Hope National Medical Center
DanTrials ApS, Copenhagen, Denmark
Dent Neuroscience Research Center
Detroit Clinical Research Center
Developmental Therapeutics Consortium
Eastern Hepatobiliary Surgery Hospital
Florida International University
German Breast Group Forschungs GmbH
Groupe Oncologie Radiotherapie Tete et Cou
GROUPE ONCOLOGIE RADIOTHERAPIE TETE ET COU
Grupo Español Multidisciplinar de Melanoma
Grupo Espanol Multidisciplinario del Cancer Digestivo
Gruppo Oncologico del Nord-Ovest
Guangzhou Trinomab Biotech Co., Ltd.
Hellenic Cooperative Oncology Group
Herbert Irving Comprehensive Cancer Center
Hospital General Universitario Gregorio Marañon
Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Hospital Universitario de Fuenlabrada
Human Stem Cell Institute, Russia
Icahn School of Medicine at Mount Sinai
Institut Hospitalier Franco-Britannique
Intergroupe Francophone de Cancerologie Thoracique
Italian Trial in Medical Oncology
James Graham Brown Cancer Center
Jyoti Clinical and Pathological Laboratory
Katholieke Universiteit Leuven
Kliniken Nordoberpfalz AG Klinikum Weiden Medizinische Kliniken I
Memorial Sloan-Kettering Cancer Center
Methodist Cancer Center, Houston, Texas
National Cheng Kung University
National Comprehensive Cancer Network
Nationales Centrum fur Tumorerkrankungen
National Institute for Health Research, United Kingdom
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Natural Science Foundation of China
Niigata University Medical & Dental Hospital
Norwegian University of Science and Technology
Ospedale Fatebenefratelli di Roma
Ospedale S. Giovanni Bellinzona
Rainier Clinical Research Center
Russian Academy of Medical Sciences
Second Military Medical University
Shahid Beheshti University of Medical Sciences
Shandong New Time Pharmaceutical Co., LTD
Shanghai Armed Police Hospital
Shanghai EpimAb Biotherapeutics Co., Ltd.
Sihuan Pharmaceutical Holdings Group Ltd.
Simcere Pharmaceutical Co., Ltd
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
State University of New York, Buffalo
Taichung Veterans General Hospital
Taipei Veteran General hospital
The Adelaide and Meath Hospital
The Christie NHS Foundation Trust
The First People's Hospital of Lianyungang
Translational Research Informatics Center, Kobe, Hyogo, Japan
Trans Tasman Radiation Oncology Group
Universidad Complutense de Madrid
Université catholique de Louvain
University of Alabama, Birmingham
University of California, Davis
University of California, Los Angeles
University of California, San Diego
University of California, San Francisco
University of Colorado, Denver
University of Erlangen-Nuremberg
University of Medicine and Dentistry of New Jersey
University of Nice Sophia Antipolis
University of North Carolina at Chapel Hill
University of Southern California
University of Western Brittany
Organization Involved with Phase 1 Indications (130)
Big Ten Cancer Research Consortium
Cancer Immunotherapy Trials Network
Casa Sollievo della Sofferenza IRCCS
Damon Runyon Cancer Research Foundation
HuaDao (Shanghai) Biomedical Co., Ltd.
James B. and Lois R. Archer Charitable Foundation
Jiangsu Hansoh Pharmaceutical Co., Ltd.
National Center for Complementary and Integrative Health (NCCIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Neurocenter of Southern Switzerland, Lugano
Organization Involved with Other Experimental Indications (21)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
